Cidara Therapeutics Commends IDSA For New Candidiasis Clinical Management Guidelines

SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, commends the Infectious Diseases Society of America (IDSA) for new clinical guidelines that recognize the important role of echinocandins in the initial treatment of invasive fungal infections.

Back to news